Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.

Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y, Tu X

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie18 Jan 2024Cited by 23 (Europe PMC)

PMID38242040DOI10.1016/j.biopha.2024.116150PepBankPUB-38242040

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity, a network meta-analysis found that semaglutide had a relatively good effect on weight loss.
In plain wordsIn adults with obesity, a pooled analysis found that semaglutide had a relatively good effect on weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss with semaglutide
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Moreover, this study indicated that orforglipron and semaglutide also had relatively good effects on weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Summary · context
A total of 29 studies with 10,333 participants were included in the present study.
Report a problemFND-3824204005
02HumanSystematic reviewEfficacy outcome
In people with obesity, the network meta-analysis reported relatively good weight loss effects for orforglipron.
In plain wordsIn people with obesity, the network meta-analysis reported weight loss effects for orforglipron.
Peptide
Orforglipron
Outcome
DecreaseWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Moreover, this study indicated that orforglipron and semaglutide also had relatively good effects on weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Report a problemFND-3824204007

Studies that did not test the peptide alone5

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome
In people with obesity, the combination of cagrilintide and semaglutide reduced body weight versus placebo in a Bayesian network meta-analysis.
In plain wordsIn people with obesity, cagrilintide combined with semaglutide lowered body weight more than placebo in this pooled analysis.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight mean difference
−14.13 kg
cagrANDsema vs placebo
Source sentences
Summary
Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73) and HbA1c by - 0.33% (95% CI: -0.41, -0.25).
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Summary · context
A total of 29 studies with 10,333 participants were included in the present study.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3824204001
04HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome
In people with obesity, the combination of cagrilintide and semaglutide reduced HbA1c versus placebo in a Bayesian network meta-analysis.
In plain wordsIn people with obesity, cagrilintide combined with semaglutide lowered HbA1c more than placebo in this pooled analysis.
Peptide
Cagrilintide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c mean difference
−0.33%
cagrANDsema vs placebo
Source sentences
Summary
Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73) and HbA1c by - 0.33% (95% CI: -0.41, -0.25).
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Summary · context
A total of 29 studies with 10,333 participants were included in the present study.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-3824204002
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, the combination of cagrilintide and semaglutide reduced weight by 14.13 kg versus placebo in a network meta-analysis.
In plain wordsIn adults with obesity, cagrilintide plus semaglutide together reduced weight more than placebo; this does not show the effect of semaglutide alone.
Peptide
Semaglutide
Outcome
DecreaseWeight change, cagrilintide plus semaglutide vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−14.13 kg
cagrANDsema vs placebo
Source sentences
Summary
Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73)
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Summary · context
A total of 29 studies with 10,333 participants were included in the present study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3824204003
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, the combination of cagrilintide and semaglutide reduced HbA1c by 0.33% versus placebo in a network meta-analysis.
In plain wordsIn adults with obesity, cagrilintide plus semaglutide together lowered HbA1c more than placebo; this does not show the effect of semaglutide alone.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change, cagrilintide plus semaglutide vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−0.33%
cagrANDsema vs placebo
Source sentences
Summary
Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73) and HbA1c by - 0.33% (95% CI: -0.41, -0.25)
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Summary · context
A total of 29 studies with 10,333 participants were included in the present study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3824204004
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, meta-regression across GLP-1 receptor agonists suggested that higher dose levels might give better weight loss.
In plain wordsIn adults with obesity, a pooled analysis of GLP-1 drugs suggested that higher doses might give more weight loss.
Peptide
Semaglutide
Outcome
Not applicableDose and weight loss (meta-regression)
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Meta-regression results indicated that higher dose levels might have better effects on weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library databases were searched for English randomized controlled trials (RCTs) on GLP-1RAs in the treatment and management of obesity published before July 18, 2023.
Summary · context
A total of 29 studies with 10,333 participants were included in the present study.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3824204006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 28 to 45Current
28 Oct 2026, 02:04 UTC
The same notice was added 18 times, first on 14 Oct 2026, 05:01 UTC. The status did not change between them.
Study results updated
Version 27
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Versions 3 to 26
13 Oct 2026, 21:46 UTC
The same notice was added 24 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.

Summary

Results from this study7

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

MeSH terms

Keywords